Nektar surges again as alopecia drug shows new promise in extension study

Nektar's Rezpegaldesleukin Shows Deepening Response in Alopecia Extension Study

Nektar Therapeutics announced that its experimental autoimmune drug, rezpegaldesleukin, demonstrated a deepening treatment response in an extension study for alopecia areata. After 52 weeks of treatment, 29% of low-dose recipients and 31% of high-dose recipients achieved a Severity of Alopecia Tool (SALT) score of 20 or below, indicating substantial hair regrowth, a mark not reached by any patient in the placebo group. This positive data, following an initial 36-week phase that did not meet statistical significance, supports the drug's advancement into late-stage testing, offering a potential alternative to existing JAK inhibitors with a cleaner safety profile.

• In the 52-week blinded extension phase of the REZOLVE-AA Phase 2 trial, rezpegaldesleukin showed a significant improvement in hair regrowth. Specifically, 29% of low-dose and 31% of high-dose recipients achieved a SALT score of 20 or below, indicating substantial hair regrowth, a mark not reached by any patient in the placebo group.
• Rezpegaldesleukin activates IL-2 on regulatory T cells to control the overactive immune response in alopecia areata. This mechanism is distinct from approved JAK inhibitors, which have been associated with blood clotting events. The drug's adverse events were reported as mild to moderate, primarily injection site reactions, with no discontinuations due to side effects in the extension phase, suggesting a potentially safer alternative.
• The positive 52-week data follows an earlier 36-week analysis where the drug did not achieve statistical significance over placebo, a result Nektar attributed to ineligible patients. The company views the extended data as strong support for advancing rezpegaldesleukin into late-stage clinical development, aiming to address the unmet need for a first-line systemic treatment option.

Rezpegaldesleukin Shows Deepening Response in Alopecia Areata

A recent pediatric study examined baricitinib (JAK-1/2 inhibitor) in 33 children aged 2-18 years with severe alopecia areata. Patients received either 2 mg or 4 mg doses for an average of 6.5 months. The study demonstrated that 45.5% of patients achieved a 50% reduction in SALT score, with good tolerance and minimal adverse events including elevated ALT, acne, and upper respiratory infection in individual patients. No serious adverse events were reported.

A large retrospective analysis evaluated topical immunotherapy using squaric acid dibutylester (SADBE) and diphenylcyclopropenone (DPCP) in 106 patients with severe alopecia areata, including 26 cases of alopecia totalis and 80 cases of alopecia universalis. The study found that 43% of patients exhibited excellent or good responses, while 75% experienced at least partial hair regrowth. Hair regrowth was observed within 4 months in 90% of responding cases, with peak therapeutic effects achieved within 3 years. Patients with concomitant atopic dermatitis showed significantly lower treatment efficacy (54% vs. 80%, p = 0.0157).

A tofacitinib study conducted in Karachi enrolled 30 subjects with various forms of alopecia areata who received oral tofacitinib 5mg twice daily. The mean SALT score improved progressively from 88.41±11.59 at baseline to 45.88±23.63 at 24 weeks, with 80% of patients demonstrating hair regrowth improvement. Notably, no adverse events were reported in any patient throughout the study duration. Additionally, a case report documented the first pediatric patient successfully transitioning from failed baricitinib therapy to ritlecitinib, achieving favorable clinical outcomes in alopecia universalis treatment.

Unpacking the REZOLVE-AA Phase 2 Extension Study Design

Recent clinical trials in alopecia areata have employed diverse study designs to evaluate both established and emerging therapeutic approaches. The most prominent studies include large-scale randomized controlled trials for JAK inhibitors, meta-analyses examining treatment efficacy, and specialized studies focusing on pediatric populations and patient-reported outcomes.

Addressing Unmet Needs in Alopecia Areata Treatment Landscape

Current treatment approaches for alopecia areata face significant systemic and clinical barriers that limit patient access and outcomes. The absence of curative therapies, combined with reimbursement challenges and inconsistent treatment effectiveness, creates substantial unmet needs in the treatment landscape.

• No curative treatment exists - all available therapies can only reduce disease activity but cannot cure alopecia areata, with management particularly challenging due to the heterogeneous and recurrent nature of the disease

• Inconsistent treatment effectiveness - none of the available therapeutic options demonstrate consistent efficacy across patient populations, making management of severe or refractory cases especially difficult

• Significant reimbursement and access barriers - alopecia areata is categorized as a lifestyle disease in Germany with no statutory health insurance coverage, while patients in Norway pay approximately 65% of direct costs and Swedish patients pay about 50%

• Limited access to approved systemic therapies - despite FDA approval of JAK inhibitors (baricitinib, ritlecitinib, and deuruxolitinib), access to these systemic drugs remains very low due to reimbursement limitations

• Geographic and demographic treatment disparities - patients in urban areas receive topical therapies more frequently than those in rural areas, and women are more likely to receive treatment than men

• Variable treatment response rates - clinical studies demonstrate significant non-response rates, with tofacitinib showing 44.4% non-response at 6 months and PUVA therapy showing reduced efficacy in patients with family history of alopecia areata

• Substantial economic and psychosocial burden - annual mean total costs reach €12,582 in Sweden and €7,677 in Norway, with indirect costs comprising 61-64% of total costs primarily due to presenteeism and long-term sick leave

• Patient dissatisfaction with symptomatic-only approaches - patients express frustration with exclusively symptomatic treatments and skepticism regarding side effects, contributing to high disease burden and treatment dissatisfaction

Rezpegaldesleukin's Safety Profile Across Alopecia Areata and Beyond

Rezpegaldesleukin, a regulatory T cell (Treg) pathway agonist and pegylated interleukin-2 cytokine prodrug, has demonstrated generally favorable tolerability in short-term clinical studies, particularly in atopic dermatitis where it was evaluated alongside other biologic therapies. In comparative analyses, biologic therapies including rezpegaldesleukin were well tolerated during short-term treatment periods, though the evidence base for this mechanistically distinct agent remains limited compared to established therapies with extensive long-term safety profiles.

The current safety assessment of rezpegaldesleukin is constrained by the availability of only small phase 2 trial data, which results in wide credible intervals and lower certainty in comparative safety rankings. Long-term safety and durability evaluation remains limited, as available analyses relied primarily on indirect comparisons anchored to short-term placebo-controlled induction periods. This limitation is particularly notable when compared to agents like dupilumab, which benefits from extensive long-term safety data spanning up to a decade of clinical experience.

Historical safety data from earlier pegylated IL-2 formulations (1989-1996) provides contextual insight into the therapeutic class, showing that PEG-IL-2 toxicity was dose-dependent and related to minimum plasma concentrations and peak level timing intervals. At therapeutic doses up to 12 million IU/m2, treatment-related toxicity was predominantly mild to moderate (WHO grades I and II), with no treatment-related mortality reported in phase I/II trials. Notably, pegylated formulations demonstrated a significant reduction in intensive care unit requirements compared to standard IL-2 therapy, suggesting improved tolerability through pegylation technology.